<DOC>
	<DOCNO>NCT01938404</DOCNO>
	<brief_summary>To assess evaluate safety octaplasâ„¢ comparison standard plasma product ( e.g. , fresh frozen plasma ( FFP ) approve plasma product use within 24 hour thaw ) use treatment TTP , patient undergo Therapeutic Plasma Exchange , special emphasis occurrence thromboembolic event ( TEEs ) .</brief_summary>
	<brief_title>Octaplas Adult TTP Trial</brief_title>
	<detailed_description />
	<mesh_term>Purpura , Thrombocytopenic</mesh_term>
	<mesh_term>Purpura</mesh_term>
	<mesh_term>Purpura , Thrombotic Thrombocytopenic</mesh_term>
	<criteria>1 . Patient male female least 18 year age old . 2 . Patient diagnosis TTP suspicion TTP plan treat TPE within 3 day study entry . 3 . Patient thrombocytopenia ( platelet &lt; 100 x 10P9P/L ) . 4 . Patient willing give voluntary write informed consent studyrelated procedure perform part standard medical care , understand consent may withdraw subject time without prejudice future medical care . 1 . Patient history severe hypersensitivity reaction plasmaderived product FFP . 2 . Patient already know IgA deficiency document antibody IgA . 3 . Patient currently participate interventional clinical study participate past 1 month prior study inclusion . 4 . Patient severe deficiency Protein S. 5 . Patient receive 1 treatment plasma exchange plasma infusion current episode TTP prior randomization . 6 . Patient currently take ACEinhibitors ; case patient ACEinhibitor treatment washout period least 24 hour elapse prior first plasma infusion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Plasma exchange</keyword>
	<keyword>Thrombotic Thrombocytopenic Purpura</keyword>
	<keyword>TTP</keyword>
</DOC>